Oppenheimer analyst Leah R. Cann maintained a Hold rating on CytomX Therapeutics Inc (NASDAQ: CTMX) today. The company’s shares closed yesterday at $22.06.
Cann wrote:
“We believe these results establish proof-of-concept for CX-072. The data are early, and we believe more data are needed to determine the role of this promising Probody. The timing of these results is as expected. Progress in parts A and B of PROCLAIM- CX-072 presented at ASCO supports our view that CytomX will advance CX-072 to be filed with FDA in 2022. Our outlook remains unchanged.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 20.0% and a 60.2% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, Crispr Therapeutics AG, and Syros Pharmaceuticals.
CytomX Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $39.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $35 and a one-year low of $13. Currently, CytomX Therapeutics Inc has an average volume of 395.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.
